Core Viewpoint - Brain-computer interface technology developer, Boruikang Technology (Shanghai) Co., Ltd., has initiated the listing guidance process with CITIC Securities, marking a significant step towards its IPO [1][3]. Company Overview - Boruikang was established on November 18, 2011, with a registered capital of 60 million yuan. The company is headquartered in Shanghai and is classified under the specialized equipment manufacturing industry [2]. - The major shareholder, Xu Honglai, directly holds 12.2453% of the shares and controls a total of 23.3332% through partnerships [2][7]. Investment and Financing - Boruikang has attracted multiple rounds of financing from notable investors, including Sequoia Capital and Baidu Ventures, with a significant B round financing exceeding 100 million yuan in March 2021 [6][9]. - The company has completed a total of 7 financing rounds, with the latest D+ round occurring in March 2025, involving several investment firms [7]. Market Potential and Industry Growth - The brain-computer interface market in China is projected to exceed 3.8 billion yuan by 2025, driven by government support and increasing market enthusiasm [4]. - The "14th Five-Year Plan" emphasizes the development of brain-computer interfaces as a new economic growth point, with substantial funds allocated in cities like Shanghai and Shenzhen [4]. Product Development and Clinical Trials - Boruikang has developed the NEO brain-computer interface system, which has successfully completed 36 surgeries on spinal cord injury patients across 11 hospitals, demonstrating its safety and feasibility [10][15]. - The company has obtained 17 technology patents and multiple certifications, positioning itself as a leader in the commercialization of brain-computer interface technology in China [14]. Future Outlook - The successful clinical trials of the NEO system may lead to it becoming the first implanted brain-computer interface product approved for market release in China [15]. - The competitive landscape is heating up, with potential IPOs from Boruikang and other companies like Qiangnao Technology, which could significantly impact the secondary market [15].

Core Insights - The market sentiment is positive, with the Shanghai Composite Index returning to 4000 points and strong performance in the Sci-Tech Innovation Board related indices [1] - The brain-computer interface (BCI) sector is experiencing a collective surge, with multiple stocks hitting the daily limit [1] - Elon Musk announced on social media that Neuralink's BCI products will enter mass production by January 1, 2026, with nearly automated surgical operations and enhanced safety features [1] Industry Developments - The first fully implanted, wireless, and fully functional BCI product developed by Brain Tiger Technology has achieved its first clinical implantation at Huashan Hospital affiliated with Fudan University [2] - On November 13, Ladder Medical announced that its self-developed "implantable wireless BCI system" entered the special review process of the National Medical Products Administration, becoming the first invasive BCI product to enter this "green channel" [2] - The 2025 BCI Conference showcased clinical progress of the NEO BCI system by Borui Kang, with 32 patients undergoing implantation across 11 hospitals, showing no adverse reactions and significant improvement in hand function [2] Technological Advancements - BCI technology is undergoing rapid iteration and upgrade, with breakthroughs in non-invasive devices improving signal quality and portability [3] - In the invasive field, the development of flexible electrodes is expected to enhance system safety, comfort, and long-term stability [3] - Multimodal integration of electromyography and electroencephalography signals is becoming a key trend for improving overall stability and reliability [3] Market Performance - As of January 5, the Sci-Tech Biomedicine ETF (588250.SH) rose by 4.93%, with its related index increasing by 5.01% [3] - Notable component stocks include BeiGene (up 11.46%), United Imaging (up 4.36%), and Eifang Bio (up 9.21%) [3] - Southwest Securities suggests focusing on three directions: overseas expansion, BCI, and AI healthcare, indicating that the 2026 market will revolve around R&D progress, commercialization, and internationalization [3]